16 completed, 5 recruiting, 4 terminated, 2 withdrawn. 7 Phase 2, 7 Phase 3, 2 Not applicable, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Active not recruiting 1 |
| Phase 3 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Eosinophilic enteropathy: new trials by email Literature Review of Eosinophilic enteropathy trials Research Report on Eosinophilic enteropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have Dupilumab - Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 22 | 2023-05-03 | 2026-07-01 |
| Study of Gastric Motility in Eosinophilic Gastritis Eosinophilic Gastritis, Gastroparesis | Recruiting | Children's Hospital Medical Center, Cincinnati | 30 | 2023-01-25 | 2026-03-31 | |
| A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis CC-93538, Placebo - Eosinophilic Gastroenteritis | Phase 3 | Completed | Celgene | 48 | 2022-03-04 | 2026-09-14 |
| National, Multicenter, Retrospective, Prospective Study to Evaluate Pediatric Gastrointestinal Eosinophilic Disorders Eosinophilic Gastrointestinal Disorders, Eosinophilic Esophagitis | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 300 | 2022-01-20 | 2024-07-25 | |
| Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) Benralizumab, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 3 | Terminated | AstraZeneca | 12 | 2022-01-18 | 2025-07-14 |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Duodenitis, Eosinophilic Gastroenteritis | Phase 3 | Completed | Allakos Inc. | 94 | 2021-05-20 | 2024-01-02 |
| Dupilumab in Eosinophilic Gastritis Dupilumab (blinded), Placebo (blinded) - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 41 | 2021-05-15 | 2025-11-04 |
| Examining the Effect of Ondansetron on Bowel Prep Success Ondansetron - Abdominal Pain, Inflammatory Bowel Diseases | Phase 4 | Completed | State University of New York - Downstate Medical Center | 41 | 2021-01-01 | 2025-10-15 |
| Eosinophilic Gastrointestinal Disorders Registry Eosinophilic Esophagitis, Eosinophilic Gastroenteritis | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 500 | 2020-12-18 | 2026-03-18 | |
| An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) lirentelimab - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Completed | Allakos Inc. | 159 | 2020-12-03 | 2024-04-22 |
| A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) lirentelimab (AK002), Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Completed | Allakos Inc. | 181 | 2020-06-18 | 2024-01-02 |
| An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002 - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Allakos Inc. | 58 | 2018-11-14 | 2024-02-28 |
| A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Allakos Inc. | 65 | 2018-07-18 | 2024-01-19 |
| Benralizumab for Eosinophilic Gastritis (BEGS) Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 26 | 2018-04-23 | 2022-02-03 |
| Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis Elemental Diet Therapy - Eosinophilic Gastroenteritis | Not applicable | Completed | Children's Hospital Medical Center, Cincinnati | 18 | 2017-09-05 | 2020-10-27 |
| Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort Eosinophilic Esophagitis, Eosinophilic Gastritis | Completed | Children's Hospital Medical Center, Cincinnati | 381 | 2016-08-01 | 2021-09-28 | |
| OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis | Recruiting | Children's Hospital Medical Center, Cincinnati | 1350 | 2015-07-17 | 2025-09-12 | |
| Sirolimus for Eosinophil-Associated Gastrointestinal Disorders sirolimus - Eosinophilic Gastroenteritis, Eosinophilic Esophagitis | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 4 | 2013-03-07 | 2018-07-05 |
| Eosinophilic Gastrointestinal Disorders Patient Registry Eosinophilic Esophagitis, Eosinophilic Gastritis | Withdrawn | Arkansas Children's Hospital Research Institute | 2013-01-01 | 2016-06-20 |
Showing 20 of 28. Sign in to see all of them.
Eosinophilic Esophagitis (18) · Gastroenteritis (5) · Digestive System Diseases (3) · Food Hypersensitivity (3) · Eosinophilia (2) · Gastritis (2) · Gastrointestinal Diseases (2) · Hypersensitivity (2) · Peanut Hypersensitivity (2) · Stomach Diseases (2) · 3-Methylglutaconic Aciduria, Type V (1) · Abdominal Pain (1) · Achalasia Addisonianism Alacrimia syndrome (1) · Acrodysostosis (1)
Gastrointestinal Diseases (22) · Digestive System Diseases (21) · Esophageal Diseases (19) · Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Esophagitis (18) · Gastroenteritis (18) · Hypersensitivity, Immediate (18) · Leukocyte Disorders (18) · Hypersensitivity (17) · Eosinophilia (16) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Intestinal Diseases (3)
AK002 (6) · benralizumab (2) · dupilumab (2) · Omalizumab (1) · Ondansetron (1) · Sirolimus (1) · cendakimab (1) · mepolizumab (1) · montelukast (1)
Children's Hospital Medical Center, Cincinnati (8) · Allakos Inc. (6) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Arkansas Children's Hospital Research Institute (1) · AstraZeneca (1) · Celgene (1) · Children's Mercy Hospital Kansas City (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Marc Rothenberg (1) · Regeneron Pharmaceuticals (1) · Sanford Health (1) · State University of New York - Downstate Medical Center (1)
United States (26) · Italy (3) · Japan (3) · Brazil (1) · Canada (1) · Netherlands (1) · Poland (1) · Spain (1) · Ukraine (1) · Vietnam (1)
Craig Paterson, MD (4) · Marc E Rothenberg, MD, PhD (3) · Calman P Prussin, M.D. (2) · Marc E. Rothenberg, MD, PhD (2) · Amelia Licari, MD (1) · Craig A Friesen (1) · Craig Patterson, MD (1) · Henrik Rasmussen, MD, PhD (1) · Joshua B Wechsler, MD (1) · Kelly D Stone, M.D. (1) · Marc E. Rothenberg, M.D., Ph.D. (1) · Marc E. Rothenberg, MD (1) · Marc Rothenberg (1)
PMID 37753954, PMID 19432972, PMID 20004787, PMID 21527026, PMID 24314292, PMID 28676207, PMID 33085861, PMID 34062314, PMID 34089846, PMID 37336228, PMID 37462600, PMID 38034452, PMID 38423296, PMID 42341804
U54AI117804 (3)